​
​

bioAffinity Stock (NASDAQ:BIAF)

RevenueOwnershipFinancialsChart
bioAffinity by TradingView

Previous Close

$1.33

52W Range

$1.21 - $3.62

50D Avg

$1.67

200D Avg

$1.99

Market Cap

$20.74M

Avg Vol (3M)

$117.41K

Beta

3.12

Div Yield

-

BIAF Company Profile

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.

Show More

Industry

Medical - Diagnostics & Research

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

75

IPO Date

Sep 01, 2022

Website

BIAF Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceDec 23
Health Care, Other$19.32K
Other Revenues$21.52K

Fiscal year ends in Dec 23 | Currency in USD

BIAF Financial Summary

Dec 23Dec 22Dec 21
Revenue-$4.80K-
Operating Income-$-4.01M$-2.21M
Net Income-$-8.15M$-6.33M
EBITDA$249.59K$-5.82M$-1.48M
Basic EPS-$-1.81$-0.86
Diluted EPS-$-1.81$-0.86

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

TickerCompany
GTHGenetron Holdings Limited
HTGMHTG Molecular Diagnostics, Inc.
BIOCBiocept, Inc.
GENEGenetic Technologies Limited
SQLSeqLL Inc.
PMDPsychemedics Corporation
TTOOT2 Biosystems, Inc.
INBSIntelligent Bio Solutions Inc.
PRPOPrecipio, Inc.